A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)
Clinical trial NCT07729956 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07729956
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-01
- Primary completion
- 2029-12-01
- Enrollment
- 436
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.